当前位置：首页>产品中心>单抗/多抗>Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody|抗人CD20和CD3ε双特异性参考抗体(靶标：人CD20/CD3)
Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody|抗人CD20和CD3ε双特异性参考抗体(靶标：人CD20/CD3)
- 货号：RB9THY257156
- 价格：面议
- 点击：617
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG4-kappa |
| 纯度 | >95% as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1.06 mg/ml |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3/Leu-4 |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 表达系统 | Mammalian Cells |
| 登录号 | P11836 & P07766 |
| 背景信息 | Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies. |
| 别名 | Bispecific, REGN-1979, 1801338-64-6 |
| 种属 | Human |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品:
